Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
Cara Therapeutics, Inc. (Nasdaq: CARA) announced a conference call for May 10, 2021, at 4:30 p.m. ET to report first quarter 2021 financial results and company updates. Interested parties can join the call by dialing (855) 445-2816 or through the live audio webcast on the company's website. Cara is advancing KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist targeting pruritus, with two Phase 3 trials showing significant itch reduction in CKD patients. The FDA has accepted the NDA for KORSUVA with a target action date of August 23, 2021.
- KORSUVA showcases promising Phase 3 trial results, demonstrating significant reduction in pruritus for CKD patients.
- FDA's acceptance of NDA for KORSUVA with Priority Review indicates strong regulatory support.
- KORSUVA's potential launch on or before August 23, 2021, could enhance market position.
- None.
STAMFORD, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 4:30 p.m. ET to report first quarter 2021 financial results and provide a corporate update.
To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 5789617. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA™ has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.
MEDIA CONTACT:
Claire LaCagnina
6 Degrees
315-765-1462
clacagnina@6degreespr.com
INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com
FAQ
When will Cara Therapeutics report its Q1 2021 financial results?
What is KORSUVA and its significance for Cara Therapeutics?
What is the FDA's decision timeline for KORSUVA?
How can I participate in the Cara Therapeutics conference call?
